Announcements Trials
Browse Landscape

Phase

Phase 4 15Phase NA 12Phase 3 8Phase 2 6Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 1Neoplasms 1Cancer Pain 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Sorafenib 110Temozolomide 109Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Completed × Morphine × Clear all
NCT00125684 2012-01-19

Bioavailability and Effectiveness of Transdermally Administered Morphine

AHS Cancer Control Alberta

Phase 1 Completed
6 enrolled

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡